Fair Value Measurements - Milestone Asset and Milestone Contingent Consideration (Details) - USD ($) $ in Thousands |
9 Months Ended | |
|---|---|---|
Sep. 30, 2024 |
Apr. 03, 2024 |
|
| Fair Value Measurements | ||
| Exarafenib milestone asset (Note 4) | $ 3,125 | |
| Exarafenib milestone contingent consideration (Note 4) | 3,125 | |
| Kinnate CVR holders | CVR Agreement | ||
| Fair Value Measurements | ||
| Exarafenib milestone asset (Note 4) | 3,100 | $ 2,900 |
| Exarafenib milestone contingent consideration (Note 4) | 3,100 | $ 2,900 |
| Increase in Exarafenib milestone asset | 200 | |
| Increase in Exarafenib milestone contingent consideration | $ 200 |
| X | ||||||||||
- Definition Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value during the period from contingent consideration liability. No definition available.
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the value during the period of milestone assets. Amount represents initial fair value in accordance with ASC 825. No definition available.
|
| X | ||||||||||
- Definition Carrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|